Researchers from CNAG-CRG and IRB Barcelona contribute to the description of the most comprehensive map of cancer genomes Blog Post

The international team of scientists of the ‘Pan-Cancer Analysis of Whole Genomes Project’ (PCAWG) today published 23 studies in the Nature journals, describing the most comprehensive map of cancer genomes from 38 types of tumours to date. Among the 1,300 researchers who have contributed to the project are scientists from the Institute for Research in Biomedicine (IRB Barcelona) and the Centro Nacional de Análisis Genómico (CNAG-CRG) in the Barcelona Science Park.The results are an important step for the development of personalised medicine to treat cancer.

 

IBEC signs an agreement with ICMS of TU Eindhoven to foster their collaboration Blog Post

The Institute for Bioengineering of Catalonia (IBEC), based in the Barcelona Science Park, and the Institute of Complex Molecular Systems (ICMS) at Eindhoven University of Technology, have signed the first agreement between the two institutes to foster their collaboration. This institutional alliance will allow to share resources, knowledge and provide mobility programs.

 

Esteve acquires German pharmaceutical company Riemser and expands its presence in Europe Blog Post

Esteve have come to an agreement to acquire the German pharmaceutical company Riemser. Headquartered in Berlin, Riemser has subsidiaries in the United Kingdom, France, and Spain and is present in nearly 50 countries through alliances with third parties. This acquisition provides Esteve ––which has its Drug Discovery and Preclinical Development Center at the Barcelona Science Park–– with greater pharmaceutical presence in Europe’s main markets and a portfolio of proprietary specialty products for hospital use. 

 

Nostrum Biodiscovery wins the 2019 of Senén Vilaró Prize for best innovative company Blog Post

Nostrum Biodiscovery (NBD), located at the Barcelona Science Park, has won the “2019 Senén Vilaró Prize for best innovative company”, one of the four awards conferred by the Board of Trustees of the University of Barcelona (UB) and the Bosch i Gimpera Foundation (FBG). The ceremony for the awards was held yesterday at the Aula Magna of the Historical Building of the UB.

 

Droplite gets €236,000 from the Neotec programme and the European Commission’s Seal of Excellence Blog Post

DROPLITE, a spin-off from the Institute of Photonic Sciences (ICFO) located in the Barcelona Science Park (PCB), has won a €236,000 grant from the Centre for the Development of Industrial Technology (CDTI) in the latest NEOTEC. The company has also earned the European Commission’s Seal of Excellence, which is awarded to start-ups that have first-class innovation ideas with great potential to open up new markets.

 

Aerie Pharmaceuticals announces agreement to acquire Avizorex Pharma for $10 Million Blog Post

La farmacèutica Aerie Pharmaceuticals, que cotitza al Nasqad, ha annunciat l’adquisició d’Avizorex Pharma (AVX Pharma), amb seu al Parc Científic de Barcelona, per un import de 10 millones de dòlares. La companyia, fundada l’any 2013 com a spin-off de la Universitat Miguel Hernandez de Elche (UMH) per l’emprenedor Patrick Tresserras i el professor Carlos Belmonte de l’Institut de Neurociencias (UMH -CSIC), està especialitzada en el desenvolupament de teràpies innovadores per a la síndrome d’ull sec.

 

Meteosim and Olfasense join forces against environmental pollution due to odours Blog Post

The Catalan company Meteosim, based at the Barcelona Science Park, has signed an alliance with the German multinationa Olfasense to provide a comprehensive solution in the smart management of bad odours and resulting conflicts. Through this alliance, the two companies integrate their leading technology in the Ortelium platform, which enables the analysis of the environmental impact of past, current and future episodes, and includes advanced complaint management tools, facilitating smart decision-making in real time.

 

Nostrum Biodiscovery joins Barcelona Science Park Blog Post

Nostrum Biodiscovery, a spin-off created thanks to the transfer of technology from the Institute for Research in Biomedicine (IRB Barcelona) and the Barcelona Supercomputing Center (BSC-CNS), has moved to Barcelona Science Park. Combining its own technologies with the best modelling software on the market, the company provides in silico services to pharmaceutical and biotechnology companies to accelerate and optimise the design of therapeutic molecules and enzymes, and overcome the common “bottlenecks” in the most initial stages of drug discovery.